Skip to main content

What the FDA labels say about taking them together

Enasidenib and rosuvastatin

Rosuvastatin's FDA label of September 4, 2026 names enasidenib in its drug interactions section; the enasidenib label PlainMeds reads does not name rosuvastatin. The rosuvastatin label: “Mechanism and Clinical Effect (s): Enasidenib increased rosuvastatin exposure more than 3.4-fold.”

Check it at the source: the enasidenib FDA label on DailyMed (effective January 16, 2025, Celgene Corporation); the rosuvastatin FDA label on DailyMed (effective September 4, 2026, ScieGen Pharmaceuticals, Inc.).

What does the enasidenib label say about rosuvastatin?

Enasidenib's label (effective January 16, 2025) does not name rosuvastatin in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Idhifa), NDA209606 (Bristol Myers Squibb), as published by Celgene Corporation, effective January 16, 2025 (SPL set a5b4cdf0-3fa8-4c6c-80f6-8d8a00e3a5b6), via openFDA; the full label on DailyMed

What does the rosuvastatin label say about enasidenib?

Rosuvastatin label, drug interactions

Mechanism and Clinical Effect (s): Enasidenib increased rosuvastatin exposure more than 3.4-fold.

Source: FDA drug label (Rosuvastatin), ScieGen Pharmaceuticals, Inc., effective September 4, 2026 (SPL set ee4933c5-0d97-494d-ac0f-2083e0100836), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

0Enasidenib generic labelers
45Rosuvastatin generic labelers
EnasidenibRosuvastatin
Labeled forLeukemia, lymphoma and myelomaHeart attack and coronary artery disease, High cholesterol, High triglycerides, Stroke prevention
Boxed warningYesNo
Pharmacy cost (NADAC)n/a$0.0692 per tablet 40 mg tablet
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?